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ABSTRACT: Medicinal leads that are also compatible with imaging technologies are attractive as they facilitate the development 
of therapeutics through direct mechanistic observations at the molecular level. In this context, the uptake and antimicrobial activi-
ties of several luminescent dinuclear Ru
II
 complexes against E. coli were assessed and compared to results obtained for another 
ESKAPE pathogen, the Gram-positive major opportunistic pathogen Enterococcus faecalis, V583. The most promising lead dis-
plays potent activity, particularly against the Gram-negative bacteria, and potency is retained in the uropathogenic multi-drug re-
sistant EC958 ST131 strain.  Exploiting the inherent luminescent properties of this complex, super-resolution STED nanoscopy was 
used to image its initial localization at/in cellular membranes and its subsequent transfer to the cell poles. Membrane damage assays 
confirm that the complex disrupts the bacterial membrane structure before internalization. Mammalian cell culture and animal mod-
el studies indicate that the complex is not toxic to eukaryotes, even at concentrations that are several orders of magnitude higher 
than its minimum inhibitory concentration (MIC). Taken together, these results have identified an entirely new lead molecular ar-
chitecture for hard-to-treat, multi-resistant, Gram-negative bacteria, which display activities that are already comparable to opti-
mized natural product-based leads. 
Although polypyridyl Ru(II) complexes have been much stud-
ied as imaging probes
1-7
 and anti-cancer therapeutic leads,
8-12
 
initial biological studies focused on their potential as antimicrobi-
als. In work that was in many ways before its time the Dwyer 
group demonstrated that lipophilic derivatives of [Ru(phen)3]
2+
 
(phen = 1,10 phenanthroline) containing methylated phen ligands 
are active against a range of bacteria, particularly Gram-positive 
species, which are unable to develop resistance to these struc-
tures.
13-15
 Since the minimum inhibitory concentrations (MIC) of 
these complexes were found to be relatively high compared to 
contemporary commercial antibacterials, this work was not fur-
ther developed. However, in the modern context of a rapidly 
emerging global health crisis due to increasing antimicrobial re-
sistance, AMR,
16-19
  the activity of such structures is being revis-
ited.
20-23
 
A notable example of these modern studies is the work of Col-
lins and Keene on oligonuclear analogues of the structures first 
reported by Dwyer.
24
 They found that tethering [Ru(phen)3]
2+
 
units together using flexible methylene-based linkers of different 
lengths produces complexes with considerably higher activity 
(lower MICs).
25,26
 The mechanism of activity for these com-
pounds is still being explored. It has been hypothesized that they 
accumulate at ribosomes, causing condensation of polysomes,
27
 
but it has also been suggested that the cellular uptake and antibac-
terial activity of this class of compounds is due to their mem-
brane-spanning ability.
28
 However, except for one notable exam-
ple involving a mononuclear complex,
29
 these systems display 
lower activity against Gram-negative species such as Escherichia 
coli. Indeed, pathogenic Gram-negative species are a particularly 
pernicious AMR problem. For example in its recent report, the 
World Health Organization declared that a post-antibiotic era is Òa 
very real possibility for the 21st centuryÓ
30
 and identified Gram-
negative Pseudomonas aeruginosa, Acinetobacter baumannii, and 
members of the Enterobacteriaceae that make up the majority of 
the ESKAPE group of serious hospital acquired infections
31
 as 
their three Priority 1 (Critical) pathogens in its "Priority Patho-
gens List For R&DÓ.
32
 The urgency of the situation is exacerbated 
by the lack of new therapeutic leads: no new class of antibiotics 
for Gram-negative pathogens has been approved for over 50 years 
and since 2010 only one new compound has entered the antibiotic 
pipeline through Phase 1 trials.
33
 This situation has prompted calls 
to increase chemical diversity in the search for new leads. 
34
 It has 
also been suggested that the lack of completely new molecular 
Òstarting points leadsÓ is the biggest roadblock for new antibiotic 
discovery. 
35
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In recent work the Thomas group have been exploring the ap-
plication of dinuclear complexes as cell probes, 
5,36-38
 therapeu-
tics
39
 and theranostics
40
 in eukaryotic cells. Apart from producing 
live cell probes, this work has led to the identification of cytotox-
ic
41
 and photo-cytotoxic leads.
42,43
 In our original report on the 
cell uptake properties of 1
4+
, we demonstrated through confocal 
microscopy that this complex was readily taken up by Gram-
positive Staphylococcus aureus.
36
 Given this fact, and the urgent 
need for new antimicrobial leads, we set out to investigate the 
therapeutic potential of related systems.  In this report, we de-
scribe the luminescent derivatives of 1
4+
, Figure 1, which display 
high activity against Gram-negative bacteria, including a patho-
genic, globally disseminated, multidrug-resistant strain. We also 
show that the most active compound is taken up by cells through 
disruption of the bacterial cell wall, consequently specifically 
localizing at the poles of cells. Such studies are greatly facilitated 
by the fact that this compound is compatible with optical micros-
copy including super-resolution techniques. 
 
Figure 1. Structures of dinuclear Ru
II
 complexes relevant to this 
report 
Results	and	Discussion	
Cell-free	studies	
Previously reported complexes 1
4+
 and 2
4+
 were synthesized 
through established procedures. 
37,42
 Inspired by the previous 
studies discussed above complexes 3
4+
 and 4
4+,
 incorporating 
methylated phen derivatives, were obtained and characterized 
through similar methods as hexafluorophosphate salts Ð see meth-
ods. Like their parent complexes, both 3
4+
 and 4
4+
 display the 
expected intense Ru
II
 →tpphz based 
3
MLCT emission in MeCN 
centred at 670 and 700 nm respectively. The biological properties 
of the four complexes were studied using their chloride salts, 
which were obtained by anion metathesis. 
As many studies have demonstrated that the balance of lipo-
philicity and hydrophilicity is crucial for live-cell uptake of bioac-
tive substrates,
5,6,43,44
 Log P for all four complexes were deter-
mined through octanol-water partition using the shake flask pro-
cedure Ð Table 1. 
These data reveal that 2
4+
 is the only truly lipophilic complex. 
However, a comparison of Log P for 1
4+
, 3
4+
, and 4
4+
 indicates 
that relative lipophilicity increases with the number of methyl 
groups attached to the ancillary ligands of these complexes. Such 
small changes can have large effects on the cell uptake and bioac-
tivity of these complexes, an issue that was explored in live cell 
studies.   
 
Table 1. Log P values for complexes 1
4+
 - 4
4+
 
Complex Log P
a 
1
4+ 
-1.77 
2
4+
 1.03 
3
4+
 -1.38 
4
4+
 -1.13 
a
Log octanol/water partition coefficients for each com-
plex was determined after 20 h at 37¡C 
Bacterial	studies	
Uptake studies of 2
4+ 
by the clinically critical Gram-negative 
bacteria found the compound was poorly soluble in complex 
aqueous media. This prompted us to design and investigate the 
uptake properties of two methylated compounds 3
4+ 
and 4
4+
. 
In these studies, we chose to investigate the wild type K12-
derivative MG1655 and uropathogenic multi-drug resistant 
EC958 ST131 strains of E. coli and, to aid comparison, we have 
also included another Gram-positive ESKAPE bacteria, the path-
ogenic gastrointestinal strain of Enterococcus faecalis, V583 
(ATCC 700802), which is a major opportunistic pathogen and 
also a leading cause of urinary tract infections. 
The minimum inhibitory concentration, MIC, of the four dinu-
clear complexes was obtained in both glucose defined minimal 
media (GDMM) and nutrient rich Mueller-Hinton-II (MH-II) as - 
whilst GDMM has been used in previous reported studies on met-
al complexes
45
 - MH-II is closer to relevant biological conditions 
and is the bacterial growth medium recommended by the Europe-
an Committee on Antimicrobial Susceptibility Testing. As 
demonstrated by the data summarized in Table 2, all four com-
plexes show higher activity in GDMM.  
Although the most lipophilic compound, 2
4+
, shows the least ac-
tivity - most likely due to its lower solubility in aqueous media - 
the lipophilic series of phen to TMP, shows an increase in lipo-
philicity and a concomitant increase in activity with 4
4+
 having 
the highest activity against all three strains of bacteria. This trend 
is consistent with the previous studies on the antimicrobial activi-
ty of polypyridyl Ru
II
 complexes.
25
 Notably, 1
4+
, 3
4+
 and 4
4+
 
showed appreciable activity against the extended β-lactam-
resistant strain of E. coli, and the vancomycin resistant strain of E. 
faecalis; complex 4
4+
 even displays higher activity than ampicillin 
against the wild type strain of E. coli. MIC data for the mononu-
clear parent compound ([Ru(Phen)2tpphz]
2+
), 5
2+
, is provided for 
comparison Ð structure given in SI. The compound exhibits a 
much lower antimicrobial activity across all strains than its dinu-
clear derivatives; however the Gram-negative selectivity is still 
observed. 
Table 2. MIC (µM) results for E. coli wild type (MG1655) 
and pathogenic (EC958) strains and E. faecalis pathogenic 
(V583) strain in GDMM and MH-II. 
Complex MG1655 EC958 V583 
GDMM values 
1
4+ 
2.3 2.8 21.3 
2
4+
 7.8 10.4 64.0 
3
4+
 2.5 2.5 8.0 
N
N
N
N
N
N
Ru Ru
N
N
N
N
N
N
N
N
4+
N N =
N N
N N N N
N N
PhPh
14+
34+ 44+
24+
 3 
4
4+
 1.2 1.6 0.5 
5
2+ 
17.5 34.9 69.8 
ampicillin 3.3 - 1.0 
MH-II values 
1
4+
 12.9 14.7 64.0 
2
4+
 139.9 145.1 64.0 
3
4+
 6.8 6.8 42.7 
4
4+
 5.6 5.6 3.3 
5
2+
 139.7 279.5 279.5 
ampicillin 5.7 - 0.5 
 
Estimates of minimum bactericidal concentration, MBC, for 5
2+
 
and 1
4+
 - 4
4+
 were also obtained and summarized in Table 3. The-
se data show that, as for the MIC data, an increase in MBC values 
between GDMM and MH-II is observed. Again, 4
4+
 is the most 
active, and in GDMM its MBC values were lower than ampicillin, 
indicating that, for all strains of bacteria, it is more active than the 
conventional antibiotic. As with the MIC data, the mononuclear 
parent compound shows a weaker activity across all strains.  
Table 3. MBC (µM) results for E. coli (MG1655, EC958 
strains) and pathogenic E. faecalis (V583 strain) in GDMM 
and MH-II. 
Complex MG1655 EC958 V583 
GDMM values 
1
4+ 
11.0 4.6 53.3 
2
4+
 15.5 25.9 85.3 
3
4+
 20.3 5.1 53.3 
4
4+
 2.4 2.4 4.0 
5
2+
 34.9 17.5 279.5 
ampicillin 11.4 - 6.3 
MH-II values 
1
4+
 44.2 58.9 128.0 
2
4+
 207.3 93.3 106.7 
3
4+
 27.0 40.5 128.0 
4
4+
 25.5 31.9 21.3 
5
2+
 139.7 297.5 558.9 
ampicillin 14.0 - 16.0 
 
Having established that complex 4
4+
 had the most promising an-
tibacterial properties, time-kill kinetics assays were carried out for 
both E. coli strains during 6 hours of exposure to increasing con-
centrations of the complex in minimal media at 37 ¡C - Figure 2.  
 
Figure 2. Complex 4
4+
 induces dose-dependent killing of E. coli 
MG1655 (A) and EC958 (B) planktonic cultures in vitro. The 
complex was added at various concentrations below and exceed-
ing the MIC, 1.2 µM (A) or 1.6 µM (B), of 4
4+
 in GDMM. Killing 
was determined by monitoring the number of colony forming 
units (CFU) per mL at time intervals up to 6 h post treatment. 
Error bars represent three independent biological repeats s 
standard deviation (SD). 
As might be expected, at concentrations lower than the MIC 
there was a gradual increase in colony forming units (CFU), as the 
bacteria continued to grow. In both strains, it is evident that, at 
concentrations of MIC and above, the compound halts the bacteri-
al proliferation and reduces the number of viable bacterial cells. 
For EC958 at the highest exposure to 4
4+
 no colonies formed, 
showing that all bacteria within the system were killed. Discrep-
ancies between MBC values and the time-kill assays may have 
arisen from different experimental conditions - the MBC assay 
involves stationary incubation over 16-18 hours, and the time kill 
assay is carried out with 90% aeration and rotation over 6 hours.  
To investigate the uptake of 4
4+
 by E. coli cells, ICP-AES (In-
ductively-coupled plasma absorbance emission spectroscopy) 
studies were carried out. As previous research had demonstrated 
that 1
4+
 is actively transported into eukaryotic cells through an 
energy-dependent mechanism, uptake studies with 4
4+
 were car-
ried out in the presence and absence of glucose - Figure 3. Exper-
iments to investigate the accumulation of ruthenium in the E. coli 
EC958 over an hour were conducted as, at high concentrations, 
the time kill assays showed 99.9% of bacteria were killed within 
the first hour of exposure to 4
4+
. In these experiments, the concen-
tration of iron, (a trace element in all cells) was also quantified as 
a control. It was found that on treatment with 4
4+
, iron content 
remained constant; furthermore, there was also a negligible 
change in CFU/mL, demonstrating that cells were not lysed dur-
ing the accumulation experiment Ð Figure 4, SI. 
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Figure 3. (I) ICP-AES data for the uptake of ruthenium by E. coli 
EC958 in the absence (A) and presence (B) of glucose after expo-
sure to 4
4+
. Ru (blue) and Fe (red) levels per cell are expressed as 
metal (g) per cell. Fe levels were calculated as a control. Condi-
tions: concentration of 4
4+
 = 0.8 µM. Cells were washed with 
0.5%(v/v) nitric acid to remove unbound complex. Error bars 
represent three independent biological repeats s SD. (II) The 
difference in Ru content per cell (g) at each time point (+) with 
glucose and (-) without glucose. Showing significant differences 
in accumulation of ruthenium in the (+) with glucose sample at 10 
and 20 minutes. Ruthenium content per cell determined via ICP-
AES. 
In glucose-free conditions, accumulation of 4
4+
 shows two 
phases: after an initial increase on exposure, low levels of ruthe-
nium are maintained for about 20 min, after which uptake gradu-
ally doubles to a final figure of 1.1 x10
-16
 g per cell. Assuming an 
average cell volume of 1  µm
3
,
48,49
 this is equivalent to an intra-
cellular concentration of >1 mM. Contrastingly, in the presence of 
glucose - although the amount of ruthenium that finally accumu-
lates is identical within experimental error - the uptake of the 
complex is rapid, with the maximum intracellular concentration of 
ruthenium being reached within 20 min. The significant differ-
ences between the glucose and glucose-free conditions are seen at 
10 and 20 minutes. 
The significant difference between experiments in the presence 
and absence of glucose at 10-20 min suggests that an energy-
dependent mechanism is - at least initially - involved in the active 
transport of 4
4+
 into cells. Furthermore, the discontinuity in uptake 
of the complex after 20 min in the absence of glucose, could sug-
gest that the complex causes damage to cell membranes that facil-
itate its passive uptake. To explore these uptake issues in more 
detail, optical microscopy studies were then carried out. 
It has been suggested that methods for direct molecular imaging 
of therapeutic leads will revolutionize the initial stages of drug 
development by providing evidence of biological activity and 
targeting capabilities.
46
 It has also been hypothesized that the use 
of super-resolution techniques toward these goals will greatly 
improve target identification and facilitate high content screen-
ing.
47
 Furthermore, as suitable imaging probes can provide high 
temporal and spatial resolution, they can be potentially used to 
directly identify the molecular mechanisms involving drug tar-
gets.
48
 As we have recently demonstrated that 1
4+
 displays excel-
lent compatibility with super resolution microscopy,
49
 we extend-
ed this work to investigate the uptake and cellular response to 
exposure to 4
4+
, thus providing an imaging study on prokaryote 
cells at super-resolution using a metal complex. Initially struc-
tured illumination microscopy
50,51
 was used to image the internal-
ization of 4
4+
 at improved resolutions (~100 nm). 
 
Figure 4. Localization of 4
4+
 in E. coli EC958 cells visualized 
through SIM at 5 min, 20 min, and 60 min. A: cells imaged using 
the emission of 4
4+
 on excitation at 450 nm using A568 filter B: 
phase contrast, C: combined image. After treatment with 0.8 µM 
4
4+
, cells were washed with nitric acid
 
before fixing with para-
formaldehyde (16 v/v %).  
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Figure 5. Localization of 4
4+
 in E. coli EC958 cells visualized through Laser Scanning Confocal Microscopy (LSCM) and Stimulated 
Emission Depletion (STED) nanoscopy at 5, 20, 60, and 120 min. Top row: cells imaged using the emission of 4
4+
 on excitation at 470 nm 
with a White Light Laser and a 470nm notch filter. Middle row: cells imaged with the same excitation and emissions settings; STED effect 
was obtained employing a 775nm depletion laser, and a 780nm vortex phase plate. Both deconvoluted diffraction-limited images (d-
LSCM) and super-resolution (d-STED) images were processed using commercial Huygens software (SVI). The arrowheads highlight re-
gions where 4
4+
 preferentially accumulates. Bottom row: normalised emission intensity profile along the solid white lines drawn on top of 
selected region of cells shown in the middle row; solid black lines represent the d-LSCM, solid red lines represent d-STED. Conditions: 
after treatment with 0.8 µM 4
4+
, cells were washed with nitric acid
 
before fixing with paraformaldehyde (16%). 
Consistent with the ICP-AES data, images obtained from the 
SIM studies indicated that 4
4+
 begins to internalize within bacteria 
after a 20 minute induction period - (Figure 4), prompting us to 
investigate this process at still higher resolutions. 
Whilst stochastic super resolution techniques such as STORM 
offer exceptionally high resolutions, their extended image accu-
mulation times make them less suited to monitoring dynamic 
processes. By contrast, stimulated emission depletion (STED) 
nanoscopy not only provides comparable sub-diffraction limited 
resolutions (down to 20nm) but, because it is a scanning based 
technique, it is also compatible with even live cell imaging.
52-54
 
Therefore we used STED to image the uptake of 4
4+
 in exception-
al detail (~50 nm) over a period of 5-120 minutes. Sample images 
taken over this time-course are shown in Figure 5. 
To investigate whether changes in cell morphology occur within 
the first 5-20 min of exposure, images were taken at the same time 
points and identical conditions used in the accumulation experi-
ments. These images confirmed that 4
4+
 is readily and rapidly 
taken up by the pathogenic strain of E. coli. Interestingly, up to 20 
min, the complex largely accumulates at cellular membranes and 
is generally distributed within the cell compartment, however, 
after this period it increasingly preferentially locates at the cell 
poles.  This distinctive distribution has also been observed in E. 
coli cells treated with the tethered oligonuclear Ru
II
 complexes 
developed by Collins and Keene, and it has been attributed to 
localization within RNA-rich polysomes.
27
  
STED microscopy was also employed for detailed 3D section-
ing experiments (3D STED). By employing a dual STED beam 
split into the XY plane and Z axis the highest possible 3D resolu-
tions in each imaged plane was facilitated; a critical factor given 
the cellular dimensions of bacteria. Using this procedure, 3D 
STED resolutions of 50 nm in each plane and around 120 nm in 
the Z-axis were obtained. 
 6 
 
Figure 6. Representative images showing section planes of full-volume deconvoluted diffraction-limited cells and super-resolution images 
(d-LSCM and d-3D STED). Normalised emission intensity profile of the solid white lines drawn on top of selected region of cells are plot-
ted. Solid black lines represent the d-LSCM, solid red lines represent d-3D STED. Zoomed-in areas of the dashed white squared drawn for 
each time point are shown adjacent to the images, as well as the orthogonal representation of every axis (XY, XZ, and YZ), where the in-
creased resolution and better localization of 4
4+
 is shown in green.  The 10 and 20 minute time points show accumulation at specific loca-
tions within the cell membrane; by the 60 minutes time point the compound localizes at sections of the cell poles as can be seen in the 
zoomed in regions (a,b,c,d). Conditions used are identical to those employed in Figure 3. 
Figure 6 shows images taken at specific time points after expo-
sure to 4
4+
. During the first 10 min the probe accumulates within 
the cell membrane forming a distinctive distribution pattern, but 
after 20 minutes dye redistribution begins and accumulation at the 
poles becomes increasingly apparent. In addition, at 20 minutes 
changes in cell morphology are observed, with lumps appearing 
on the membrane. 
Taken together with the ICP-AES data, the SIM and STED imag-
ing studies indicate a change in the quality of uptake and intracel-
lular distribution of the complex after around 20 min. Further-
more, as the molecular weight of 4
4+
 is considerably larger than 
the upper limit for porin-mediated uptake (~600 Da), this mecha-
nism can be discounted.
17
 To investigate the possibility of mem-
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brane damage a second co-staining experiment with the probe 
Alexa Fluor NHS-ester 405 was carried out - Figure 7.  
 
Figure 7. Co-localization of 4
4+
 and NHS-ester 405 in E. coli 
EC958 cells visualized through SIM at 5 min (left), and 60 min 
(right). i. Cells were treated with 0.8 µM 4
4+
, then washed with 
nitric acid
 
before fixing with paraformaldehyde (16%). After fixa-
tion cells were treated with 2.5 µg/mL of NHS-ester 405. Top 
panel:  emission of 4
4+
 (A568 filter) middle panel: NHS-ester 405 
emission at 405 nm (DAPI filter Bottom panel: merged images.  
ii. Staining with NHS-ester in the absence of 4
4+
. 
Since Alexa Fluor NHS-ester 405 is impermeable to non-
compromised bacterial membranes it localizes and images cell 
membranes.  Following 5 min exposure to 4
4+
, localization of 
NHS-ester 405 is - as expected - restricted to the cell membrane 
of bacteria. However, after 60 min exposure to the complex, both 
dyes are found to internalize within E. coli. In contrast, even after 
60 min, cells solely stained with NHS-ester 405 continue exclu-
sively to display membrane staining. The fact that the membrane 
stain is internalized only after treatment with 4
4+
 offers further 
evidence that the complex is disrupting the structure of bacterial 
membranes. To investigate this phenomenon more quantitatively, 
concentration-dependent ATP cellular leakage assays were per-
formed.
55
 Following treatment with specific concentrations of 4
4+
, 
the presence of extracellular ATP, released from damage to bacte-
rial cell membranes, was detected using the luminescence gener-
ated from the ATP-dependent reaction between recombinant fire-
fly luciferase and D-luciferin.  
 
Figure 8. Determination of 4
4+
-induced ATP released from E. coli 
EC958 cells. Extracellular [ATP] (nM) quantified with recombi-
nant luciferase and D-luciferin, with ATP released measured on a 
luminometer for samples exposed to 0 (control), 0.8, and 1.6 µM 
(MIC) of 4
4+
 over a period of two hours. A three-star significant 
difference is observed between 0 and 1 MIC, P value = 0.0006. 
Error bars represent three biological repeats s SD. Inset: ATP 
positive control Ð polymyxin 4 µg/mL. 
Data obtained from the luminescence-based determination of 
[ATP], summarized in Fig 8, confirm that bacterial membranes 
are compromised in a concentration-dependent manner on expo-
sure to 4
4+
. Given this effect it seems likely that the uptake of the 
complex in glucose-free conditions is biphasic, as membrane 
damage must initially occur before the level of internalized 4
4+
 
can rise to high concentration. The significant ATP release, sup-
ported with the observation of membrane binding at the nanoscale 
and internalisation of NHS-ester signifies that membrane damage 
is the mechanism of therapeutic action  
To further investigate this issue, the effect of  4
4+
 on membrane 
potential was studied using the dye DiOC2(3). Following exposure 
to this complex, a shift in the intramolecular emission of the dye 
from green to red was observed when EC958 cells were treated at 
MIC concentrationÐ Figure 7, SI. This shift in emission is associ-
ated with larger membrane potentials causing DiOC2(3) to self-
associate at higher cytosolic concentrations. Again, this observa-
tion indicates that 4
4+
  disrupts membrane function.
56
 
To understand the true extent of the membrane damage Trans-
mission Electron Microscopy (TEM) was used to image structural 
changes induced by exposure to 4
4
+Ð Figure 9.  
E. coli EC958 cells were treated with 4
4+
 at concentrations below 
and at the MIC and then fixed and imaged at zero to two hours 
after exposure. As 4
4+
contains two electron dense Ru
JJ
 moieties it 
functions as a TEM contrast agent in itself. In comparison to the 
control (0 minutes) the outer membrane is not clearly observed at 
the two later time-points.  
In both treatment regimes after one hour exposure the majority of 
cells display visibly damaged membrane structures and blebbing 
of the membrane is observed in a number of cases. After two 
hours exposure the outer membrane (OM) is mostly detached 
resulting in a large amount of cell debris likely caused by cell 
lysis. These TEM images confirm the compound causes damage 
to both membranes.  
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Figure 9.  Localization of 4
4+
 in E. coli EC958 cells visualized 
through Transmission Electron Microscopy at 0 (A) and 10 
minutes (B) at MIC concentration. Later time-point images at 1 (I) 
and 2 hours (II). After treatment with 0.5MIC (C) and MIC (D) 
concentrations of 4
4+
. Directly using the complex as a contrast 
agent to show accumulation of 4
4+ 
in the cell membrane. OM, 
peptidoglycan layer (PG) and plasma membrane (PM) are identi-
fied in AI. Cells were fixed with osmium tetroxide. 
 
As 4
4+
 shows high antimicrobial activity and is membrane tar-
geting, the potency of the compound in non-cancerous human 
cells was determined to further explore its potential as an antimi-
crobial theranostic lead. MTT-assays on the human embryonic 
kidney line, HEK293 revealed an average IC50 value of 135 µM, 
indicating at least an 80-fold magnitude difference in inhibitory 
concentration against bacteria and HEK293 cells Ð Table 4. 
Table 4. Ratio of MIC (µM) and HEK293 IC50 values for 
each strain of bacteria.  
Cell line MIC (µM) IC50/MIC 
E. coli EC958 1.6 84.4 
E. coli MG1655 1.2 112.5 
E. faecalis V583 0.5 270 
 
Given the promising comparison between IC50 and MIC values 
an animal model screen was carried out. As many aspects of the 
physiology of Galleria mellonella larvae, particularly their im-
mune system, are very similar to mammal  they are much em-
ployed as an in vivo model, 
57,58
 including as a toxicity screen, 
59,60
 yielding results that are comparable to commonly used 
mammalian models.  A toxicity screen was conducted with 4
4+
 
and Kaplan-Meier survival curves plotted - Figure 10. 
All concentrations used were above the MIC for 4
4+
 against 
EC958, and within the daily dose range used in the clinic for an-
timicrobials. From Log-rank tests it was determined that there was 
no significant difference between the percentage survival with the 
Galleria treated with 4
4+
 and the control at all compound concen-
trations. In addition, activity and melanisation scores showed that 
there was no significant negative effects on the Galleria exposed 
to 4
4+
, confirming that this compound is not toxic at concentra-
tions well above the MIC. 
 
Figure 10. (A) Galleria melonella toxicity screen Kaplan-Meier 
survival curves, cells treated with 0-80 mg/kg of [4
4+
]Cl4, incu-
bated at 37.5 ¼C for 120 hours Ð control (black), compound (red). 
(B) (I) Activity score data from the Galleria collected every 24 
hours for 120 hours, experimental determination of the activity 
scores given in the experimental section of the SI. (II) Melanisa-
tion score data from the Galleria study, experimental determina-
tion of the melanisation scores given in the experimental section 
of the SI. 
Conclusions	
Faced by the challenges presented by the emergence and rapid 
increase in multi-resistant bacterial infections, recent reports have 
highlighted the need to develop radically new approaches toward 
the discovery of antibiotics.
18,31,61-63
 In the context of the failure 
of traditional high throughput screening, there has also been a call 
to sample new chemical spaces in the hope of identifying leads 
with novel activity,
31,34,61,64-66
 that function through multiple 
mechanisms
35
 and/or target and disrupt membranes.
67
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Although mononuclear transition metal complexes and oligonu-
clear complexes linked by flexible tethers have been investigated, 
there has been little work on dinuclear systems linked by a rigid 
extended aromatic bridging ligand, an architecture that offers 
particular merits for activity against Gram negative bacteria. Pre-
vious reports have highlighted the distinctive biophysical proper-
ties a species must possess to be active against Gram-negative 
pathogens,
68-70
 indicating that - compared to typical drug architec-
tures - active systems should be more complex 3-D structures, 
polar, possess potentially ionizable nitrogen sites, and be rigid. 
Furthermore, it has been suggested the poor hit rate for discovery 
is due to a lack of more polar systems in high throughput screen-
ing libraries.
69
  As the systems discussed in this report meet all 
the above criteria it is perhaps not surprising that they display 
such promising activity. Given that no significant new organic 
antibiotic that is selectively effective against Gram-negative bac-
teria has been developed in the past five decades, this study pro-
vides further evidence that there is considerable potential in ex-
ploiting the Ru
II
 coordination sphere as a Ôchemical spaceÕ for the 
generation of novel antimicrobial structures. This is further illus-
trated by the fact that the systems described herein are already 
considerably more active than recently reported natural product 
analogues that were optimized as Gram-negative therapeutic 
leads.
71
.  
It is possible that the therapeutic mechanism of complex 4
4+
 
solely involves its membrane targeting properties; although - once 
internalized - it localizes and binds at specific regions within cells, 
suggesting a second cellular target. Indeed as pathogenic, thera-
peutically-resistant, strains of E. coli are still sensitive to the com-
plex, it seems likely that the membrane disruption effect of 4
4+
 
may only be one facet of a more complex set of interactions and 
cellular responses.  
Future studies will fully delineate the action of the compounds 
at a molecular scale. For example, as uptake appears to take place 
by both energy-dependent and -independent mechanisms, work to 
identify how membrane disruption occurs is underway. The bio-
logical significance of localization of  4
4+
 at the poles of the cell 
compartment, which may also be basis of the apparent selectivity 
towards Gram-negative species, is also being investigated. All 
these studies  will be facilitated by the fact that such systems are 
simultaneously excellent imaging agent for super resolution mi-
croscopy techniques and TEM, allowing sub-cellular localization, 
molecular targeting, and therapeutic action to be directly 
probed.
36,49
 
 
Methods 
Chemistry Methods 
The ligand tpphz was synthesized using a reported procedure.
42
 
 [Ru(N-N)2Cl2]
72 
Four compounds were synthesised by the following method, 
where N-N represents the substituted phenanthroline ancillary 
ligand. RuCl3.3H2O, N-N and LiCl were heated in DMF for 8 
hours under reflux. The reaction mixture was cooled to room tem-
perature and acetone added. This was stored at 4 ûC for 16 hours. 
The dark purple precipitate was washed with water and ethanol 
and dried in vacuo.  
 
[Ru(1,10-phenanthroline)2Cl2] 
RuCl3.3H2O (1.56 g, 6 mmol), LiCL (1.55 g, 36.9 mmol), phen 
(2.5 g, 13.9 mmol), DMF (20 mL) and acetone (100 mL). Mass = 
2.41 g (4.59 mmol, 66.1 % yield). ES-MS m/z (%): 497 (70) [M-
Cl]
+
, 525 (100) [M-Cl]
+
+CO. 
[Ru(4,7-diphenyl-1,10-phenanthroline)2Cl2] 
RuCl3.3H2O (1.05 g, 4.15 mmol), DIP (2.3 g, 6.92 mmol), LiCl 
(1.04 g, 24.50 mmol), DMF (18 mL) and acetone (100 mL) Mass 
= 2.15 g (2.59 mmol, 68.9 % yield) black-purple crystal solid. MS 
m/z (%): 801.0 (15) [M-Cl]
+
, 829.0 (100) [M]
+
. Carbon monoxide 
displaced one of the chlorines. 
[Ru(2,9-dimethyl-1,10-phenanthroline)2Cl2] 
RuCl3.3H2O (1.56 g, 6 mmol), LiCL (1.55 g, 36.9 mmol), DMP 
(phenanthroline (2.5 g, 12 mmol), DMF (20 mL), acetone (100 
mL). Mass = 2.32 g (3.99 mmol, 66.6 % yield). ES-MS m/z (%): 
552.9 (100) [M-Cl]+, 580.9 (100) [M-Cl]
+
+CO.  
[Ru(3,4,7,8-tetramethyl -1,10-phenanthroline)2Cl2] 
RuCl3.3H2O (1.14 g, 5.50 mmol), TMP (2.4 g, 10.16 mmol), LiCl 
(1.47 g, 34.68 mmol), DMF (19 mL) and acetone (100 mL). Mass 
= 2.07 g (3.21 mmol, 63.2 %) purple solid. MS m/z (%): 609.1 
(62) [M-Cl]
+
, 637.1 (100) [M]
+
 667.1  (44) [M+Na]
+
. Carbon 
monoxide displaced one of the chlorines.  
[{Ru(N-N)2}2(tpphz)][PF6]4 
The four compounds were synthesized by the following general 
procedure.
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 [Ru(N-N)2Cl2] and (tpphz) were added to a 1:1 solu-
tion of ethanol and water. The solution was heated at reflux for 12 
hours under nitrogen. After completion the reaction mixture was 
cooled to room temperature and stored at 4  C for 16 hours. The 
red solution was filtered and the ethanol removed by rotary evap-
oration. A saturating amount of NH4PF6 was added; this caused 
the formation of a dark red precipitate. The precipitate was col-
lected by filtration, washed with water and recrystallized in ace-
tonitrile by addition of diethyl ether. The product was dried in 
vacuo and purified on an alumina column, using the following 
solvent system: was 95% MeCN, 3% dH2O and 2% KNO3. 
 
[{Ru(1,10-phenanthroline)2}2(tpphz)][PF6]4 
Tpphz (0.263g, 0.68 mmol), [Ru(phen)2Cl2] (1g, 1.89 mmol) and 
ethanol/water (50 mL). Mass = 1.1 g (0.58 mmol, 85.6 % yield). 
1
H NMR (MeCN-d
6
) δ (splitting integration): 7.71 (m, 8H), 7.94 
(dd, 4H), 8.09 (d, 4H), 8.29 (dd, 8H), 8.33 (s, 8H), 8.69 (dd, 8H), 
10.01 (dd, 4H). ES-MS; m/z (%): 799 (10) [M-2PF6]
2+
, 484 (15) 
[M-3PF6]
3+
, 321 (50) [M-4PF6]
4+
, Accurate mass analysis: 
C72H28N14[
102
Ru]2
4+
 Calculated 321.1110. Found 321.1112. 
[{Ru(4,7-diphenyl-1,10-phenanthroline)2}2(tpphz)][PF6]4 
[Ru(DIP)2Cl2] (1.47 g, 1.76 mmol), tpphz (0.234 g, 0.61 mmol) 
and ethanol/water (80 mL). Mass = 1.21 g (0.48 mmol, 78.7 %) 
red-brown solid. 
1
H NMR (MeCN-d
6
) δ (splitting integration): 
7.66 (m, 40H), 7.7 (d, 8H), 8.0 (dd, 4H), 8.27 (s, 8H), 8.3 (d, 4H), 
8.4 (dd, 4H), 8.5 (d, 4H), 10.0 (d, 4H).  MS; m/z (%): 1103 (35) 
[M-2(PF6)]
2+
, 687 (88) [M-3(PF6)]
3+
, 479 (56) [M-4(PF6)]
4+
. 7.7 
(m, 40H), 7.84 (d, 4H), 7.81 (dd, 4H), 8.1 (dd, 4H), 8.4 (s, 8H), 
8.68 (d, 4H), 8.74 (dd, 8H), 10.2 (d, 4H). Accurate mass analysis: 
C120H76N14[
102
Ru]2
4+
 Calculated 479.1111. Found 479.1110. Ele-
mental analysis [{(Ru(DIP)2}2(tpphz)] (NO3)4.10H2O, 
C120H96N18O22Ru2: Calcd: C; 61.48, H; 4.12, N; 10.75. Found: C; 
61.83, H; 4.36, N; 10.50. 
 
[{Ru(2,9-dimethyl-1,10-phenanthroline)2}2(tpphz)][PF6]4 
Tpphz (0.263 g, 0.68 mmol), [Ru(dmp)2Cl2] (1.02 g, 1.73 mmol) 
and ethanol/water (50 mL). Mass = 0.98 g (0.49 mmol, 72 % 
yield). 
1
H NMR (MeCN-d
6
) δ (splitting integration): 2.34 (s, 
24H), 7.30 (d, 4H), 7.59 (m, 8H), 7.90 (d, 4H), 8.20 (d, 4H), 8.37 
(t, 8H), 8.83 (d, 4H), 9.80 (d, 4H). ES-MS; m/z (%): 855 (8) [M-
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2PF6]
2+
, 522 (70) [M-3PF6]
3+
, 355 (10) [M-4PF6]
4+
, Accurate 
mass analysis: C80H52N14[
102
Ru]2
4+
 Calculated 355.1111. Found 
355.1112. Elemental analysis for 
[{Ru(DMP)2}2(tpphz)](PF6)4.2H2O, C80H64F24N14O2P4Ru2: 
Calcd: C; 47.21, H; 3.17, N; 9.63. Found: C; 46.09, H; 3.17, N; 
9.71. 
[{Ru(3,4,7,8-tetramethyl-1,10-
phenanthroline)2}2(tpphz)][PF6]4 
[Ru(TMP)2Cl2] (1.12 g, 1.73 mmol) and tpphz (0.260 g, 0.68 
mmol), water/ethanol (80 mL). Mass = 1.22 g (0.58 mmol, 85.7 % 
yield). MS; m/z (%): 911 (10) [M-2(PF6)]
2+
, 559 (100) [M-
3(PF6)]
3+
. 
1 
HNMR (MeCN-d
6
) δ (splitting integration): 2.1 (s, 48 
H), 7.8 (s, 4H), 7.9 (t, 8H), 8.2 (dd, 4H), 8.4 (s, 8H), 9.9 (dd, 4H). 
1 
HNMR (Acetone-d
6
) δ (splitting integration): 2.1 (dt, 48H), 8.0 
(m, 4H), 8.1 (s, 4H), 8.2 (s, 4H), 8.52 (d, 4H), 8.6 (s, 8 H) , 10.1 
(d, 4H). Elemental analysis [{Ru(3, 4, 7, 8-Tetramethyl-1,10-
phenanthroline)2}2(tpphz)] (PF6)4.5.5H2O, C88H87N14O5.5Ru2P4F24 
Calculated: C; 47.93, H; 3.97, N: 8.89. Found C; 47.92, H; 3.83, 
N; 8.82. Accurate mass analysis: C88H76N14[
102
Ru]2
4+
 Calculated 
383.1111. Found 383.1112.  
[{Ru(1,10-phenanthroline)}2(DPQ)][PF6]2 
[Ru(Phen)2Cl2] (1.01 g, 1.90 mmol), DPQ (0.495 g, 2.36 mmol) 
and EtOH:H2O (50 mL). Mass = 0.910 g (0.946 mmol, 49.8 %). 
MS (TOF MS LD+) m/z (%): 671 (100) [M-2PF6]
2+
, 817 (50) [M-
PF6]
+
. 
1 
HNMR (DMSO-d
6
) δ (splitting integration): 7.52 (2H, 
dd), 7.63 (2H, dd), 7.85 (2H, dd), 7.94 (4H, dd), 8.30 (4H, q), 8.37 
(2H, dd), 8.51 (2H, dd), 8.62 (2H, dd), 8.73 (2H, dd). 
 
[Ru(Phen)2(tpphz)][PF6]2 
5,6-diamino-1,10-phenanthroline (100 mg, 0.48 mmol), hot meth-
anol (20 mL), [Ru(Phen)2DPQ][PF6]2 (650 mg, 0.71 mmol), ace-
tonitrile (30 mL). Mass = 0.251 g (0.221 mmol, 31.1%). , 
1 
HNMR (CD3CN-d
6
) δ (splitting integration): 7.76 (8H, m), 8.19 
(4H, dd), 8.34 (4H, dd), 8.68 (4H, t), 8.80 (2H, d), 9.43 (4H, dd). 
MS; m/z (%): 991.4 [M-PF6]
+
 (100); 845.4 [M-2PF6]
+
 (35); 423.2 
[M-2PF6]
2+
 (25). C48H28N10[
102
Ru]
2+ 
Calculated 423.0765. Found 
423.0783.  
 
Anion metathesis 
The hexafluorophosphate salt of each complex was dissolved in 
the minimum volume of acetone and a saturated solution of tet-
rabutylammonium chloride in acetone added. The resultant pre-
cipitated chloride salt was collected by filtration, washed with 
cold acetone and dried in vacuo. 
 
Absorption spectra 
An emission quartz cuvette was loaded with varying concentra-
tions of the [Ru(TMP)2(tpphz)] chloride salt dissolved in water (0-
20 µM). Each reading was baseline corrected. The absorption 
spectra at 200-800 nm were obtained with a Cary 500 Scan UV-
vis-NIR Spectrophotomer, set to double beam mode (spectral 
band width = 2 nm), with a medium scan speed of 600 nm min
-1
. 
 
Molar extinction coefficients 
Molar extinction coefficients were calculated using the Beer-
Lambert law. They were calculated from a plot of measured ab-
sorbance against sample concentration.  
! ! ���  Equation 5.1: Beer-Lambert Law 
 
Excitation and emission spectra 
A fluorescence quartz cuvette was loaded with varying concentra-
tion of the [Ru(TMP)2(tpphz)]
2+
 chloride salt dissolved in water 
(0-20 µM). The excitation and emission spectra were recorded 
using a Fluoromax-3 Spectrophotometer, slit width 5 nm, scan 
speed 100 nm min
-1
. The emission spectra were taken at the 424 
nm peak seen in the absorption spectra. 
Determination of LogP 
Relative lipophilicities or partition coefficients of 1
4+
 - 4
4+
 across 
l-octanol and H2O (logPoct/wat) were determined via the shake-
flask method.
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Aqueous stocks of 1
4+
 - 4
4+
 were prepared at 200 
and 300 µg mL
-1 
were added to equal volumes of 1-octanol that 
had been pre-saturated with H2O for 36 h. After incubation with 
shaking at 37 ¡C for 24 h, the 1-octanol and aqueous phases were 
recovered and the relative distribution of each compound was 
determined by UV-vis absorbance spectroscopy at 430 Ð 455 nm.  
 
Microbiology and Microscopy Methods 
Bacterial strain information and general growth procedures 
Microbiological studies were conducted with: (1) wild-type K-12 
derivative laboratory strain Escherichia coli MG1655; (2) CTX-
M-15 type extended spectrum β-lactamase (EBSL)-producing 
clinical isolate E. coli EC958 (ST131)
75
 and (3) Enterococcus 
faecalis vancomycin-resistant V583 clinical isolate (ATCC 
700802).
76
 Bacteria were routinely grown under aseptic, aerobic 
conditions in autoclave-sterilised culture medium at 37 ¡C. Lyso-
geny Broth (LB) (Formedium), Mueller-Hinton II (MH-II) (Sig-
ma-Aldrich) and Brain-Heart Infusion (BHI) (Sigma-Aldrich) 
were prepared as per manufacturersÕ instructions. Glucose defined 
minimal medium (GDMM) was prepared by dissolution of 4 g L
-1
 
K2PO4, 1 g L
-1
 KH2PO4, 1 g L
-1
 NH4Cl, 10 mg L
-1
 CaCl2 and 2.6 g 
L
-1
 K2SO4 in deionized H2O with supplementation of 10 mL L
-1
 
Trace Elements solution. The pH was adjusted to 7.4 by the addi-
tion of NaOH. GDMM was sterilised by autoclaving and then 
further supplemented with 1 mM MgCl2 and 20 mM glucose prior 
to growth studies. Trace elements contained 5 g L
-1
 ethylenedia-
minetetraacetic acid (EDTA), 0.5 g L
-1
 Fe(III)Cl3.6H2O, 50 mg L
-
1
 ZnO, 10 mg L
-1
 CuCl2.2H2O, 10 mg L
-1
 CoNO3.6H2O, 10 mg L
-
1
 H3BO3, 0.12 mg L
-1
 (NH4)2MoO4 and 17 mg L
-1
  Na2O4Se. 
 
Prior to experiments, bacterial starter cultures were prepared by 
inoculating LB (E. coli) or BHI (E.  faecalis) with a single colony 
of bacteria and then grown for overnight at 37 ¡C with shaking for 
16 Ð 18 h. For E. coli EC958 and E. faecalis V583, starter cultures 
were additionally supplemented with 50 µg mL
-1
 ampicillin or 10 
µg mL
-1 
vancomycin. Starter cultures were washed once and re-
suspended in the appropriate growth medium for each experiment.  
For short-term storage, bacterial stocks were maintained on nutri-
ent agar plates at 4 ¡C for 2 Ð 3 weeks. For long-term storage, 
strains were stored as cell suspensions in 30 % (v/v) LB 70 % 
(w/v) glycerol at Ð 70 ¡C. 
 
Determination of Minimum Inhibitory Concentrations (MICs) 
and Minimum Bactericidal Concentrations (MBCs) 
MICs and MBCs of 1
4+
 - 4
4+
 and ampicillin (comparison) were 
determined via the standard broth-dilution method in 96-well 
microtitre plates in either MH-II, as recommended by European 
Committee of Antimicrobial Susceptibility Testing (EUCAST) or 
in GDMM. For E. faecalis, both media were further supplemented 
with 10 % (v/v) BHI to facilitate growth. The MIC of each com-
pound was evaluated using 2-fold increasing concentrations of 
each compound between 2  - 512 µg mL
-1
 against a bacterial inoc-
ulum of 10
7
 Ð 10
9
 colony forming units per mL (CFU mL
-1
), cor-
responding to an optical density at 600 nm (OD600) of 0.05 Ð 
0.075. Plates were incubated at 37 ¡C for 20 h. After this time, the 
level of turbidity in each well was used to determine the extent 
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bacterial cell growth in the presence of the compounds. The min-
imal concentration of compound that did not permit bacterial 
growth was determined to be the MIC. For MBC determination, 
10 µL samples of each well were then transferred to nutrient agar 
plates and further incubated at 37 ¡C. The lowest concentration of 
compound in which no CFU were observed after plating was de-
termined to be the MBC. MIC/MBCs were determined from 3 
independent biological repeats. 
 
Cytotoxicity MTT assays  
Yellow MTT (3-(4,5-dimethylthiazol-2-yl)2,5-
diphenyltetrazolium bromide) is reduced to a purple formazan 
product in the mitochondria of living cells by reductase enzymes. 
The reduction of MTT can only occur within active mitochondria, 
therefore the amount of formazan produced is directly related to 
the number of viable cells in the sample. In this experiment the 
amount of formazan was quantified by absorbance between 500-
600 nm, the toxicity of the compound was deduced by comparison 
of formazan content for cells exposed to the compound and those 
in the untreated control.  
 
IC50 values 
Cell cultures were grown on 24 or 48 well plates and allowed to 
grow for 24 hours. Cell cultures were then treated with solutions 
of the Ru(II) complex at various concentrations (10% PBS: 90% 
medium) for the given incubation time in triplicate. Solutions 
were removed and the cells incubated with 0.5 mg ml-1 MTT 
dissolved in PBS for 30-40 minutes. The formazan product was 
eluted using 200 µl/well of acidified propan-2-ol, 150 µl of this 
was transferred to a 96 well plate and the absorbance quantified 
by spectrophotometer (540 nm, referenced at 640 nm). An aver-
age absorbance for each concentration was obtained and cell via-
bility was determined as a percentage of untreated negative con-
trol wells (10% PBS: 90% medium). Using Sigmaplot 11.0 soft-
ware, a 3 parameter sigmoidal curve was used to fit each data set 
(R2 > 0.97 for each fit) and the IC50 value (the concentration 
corresponding to 50% viability) calculated by interpolation.   
 
Time-kill assays 
E. coli MG1655 and EC958 strains were grown on GDMM to 
early exponential phase, diluted to approximately 10
8
-10
9
 CFU 
mL
-1
 and 4
4+
 was added at 0 Ð 25.6 µM (0 - 8 x MIC). Immediate-
ly prior to TMP addition, and at 1-6 h thereafter, culture growth 
(turbidity at OD600) and viability (CFU mL
-1
) were measured. Cell 
viability was determined via the standard viable counts method, 
which is based on the ability of a single viable bacterial cell to 
form a colony when grown on agar plates. 10-fold serial dilutions 
of cell culture samples were prepared in sterile PBS and then 3 x 
10 µL of each dilution was spotted onto nutrient agar plates. 
Plates were then incubated overnight at 37 ¡C to permit colony 
growth and cell viability was determined as the average number 
of counted CFU mL
-1
. Time-kill assays were performed as three 
independent biological repeats. 
 
Uptake of 4
4+
 by E. coli and determination of cellular rutheni-
um and iron levels 
Uptake and cellular accumulation of 4
4+
 by E. coli EC958 was 
determined by measuring bacterial cell metal content by Induc-
tively Coupled Plasma-Atomic Emission Spectroscopy (ICP-
AES) as follows. E. coli EC958 cultures were grown to mid-
exponential phase in LB broth, washed in PBS and then resus-
pended in PBS +/- 20 mM glucose to approximately 10
8
-10
9
 CFU 
mL
-1
. 4
4+
 was added to cells at MIC level (1.6 µM) and then 20 
mL samples of culture were harvested at 5, 10, 20 and 60 min 
after 4
4+
 addition. Samples of non-4
4+
 treated cells were also taken 
for comparison. Samples were centrifuged at 5,000 x g for 20 min 
at 4 ¡C to obtain cell pellets and the supernatant containing un-
bound extracellular 4
4+
 was discarded. The resultant cell pellets 
were then washed twice in 0.5 % (v/v) Aristar nitric acid to re-
move loosely bound residual 4
4+
. To prepare cell material for ICP-
AES, cell pellets were resuspended in 0.5 mL Aristar nitric acid 
(69 % (w/v) and then placed in a sonicator bath for 30 min to 
completely dissolve cells. The resulting digest was then diluted to 
a final volume of 5 mL with diluted nitric acid and then samples 
were analysed on a Spectro CirosCCD (Spectro Analysis) Induc-
tively-Coupled Plasma-Atomic Emission Spectrophotometer. 
Levels of Ru and Fe in the samples were determined by a calibra-
tion curve using multi-element standard solutions containing 0.1, 
0.2, 5 and 10 mg L
-1
 Ru and Fe.  
 
Membrane damage ATP release assays 
Loss of E. coli membrane integrity following 4
4+
 exposure was 
determined by leakage of ATP, an intracellular marker, from E. 
coli cells.
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 Levels of extracellular ATP of E. coli grown with or 
without 4
4+
 were determined as follows. E. coli EC958 cells were 
grown to mid-exponential phase in GDMM and then 4
4+
 (0 Ð 1.6 
µM) was added to cultures. Immediately prior to, and at time-
intervals after 4
4+
 addition, samples of cell culture were harvested 
by centrifugation at 15, 000 x g for 5 min at 4 ¡C to remove cells. 
Supernatants were recovered and retained at Ð 20 ¡C for ATP 
analysis. ATP analysis was conducted using the bioluminescence-
based Molecular ProbesÕ ATP Determination kit (Invitrogen, 
Fisher Scientific). The levels of ATP in supernatants were derived 
via a standard curve of ATP standards from 1 nM - 1 µM. Lumi-
nescence measurements of ATP standards and culture superna-
tants were measured in duplicate on a Lumat
3
 Luminometer 
(Berthhold Technologies, UK).  
 
Single stain microscopy 
Preparing the culture 
An overnight culture of bacteria (EC958) was grown in LB. The 
cells were washed (x2) and resuspended in GDMM. The cells 
were diluted to OD600-0.05 and grown to OD-0.3-0.4 in GDMM 
(50 mL). 1 mL of culture was harvested, and the compound added 
at MIC concentration. 1 mL cultures were then harvested at 5, 10, 
20 and 60 minutes. The bacteria were pelleted (centrifuge, 14,000 
RPM, 90 seconds), and supernatant removed. The pellet was sus-
pended in fixant (16% paraformaldehyde in PBS, 500 µL) and 
Milli-Q water (500 µL) and placed on a rotary wheel at room 
temperature for 30 minutes. The samples were washed in PBS and 
frozen as a pellet.  
Preparing the slides 
Coverslips were sonicated in 1M KOH for 15 minutes, then coat-
ed in polylysine solution for 30 minutes. The pellets were sus-
pended in 5 µL of a SlowFade Gold Antifade Mountant (Ther-
mofisher). The suspension was mounted onto the slide and the 
coverslip placed on top. Slides were imaged using the structured 
illumination (SIM) microscope. Imaging was done using the 1514 
immersion oil, and mol_probes microscope setting. A phase con-
trast image was taken (DIC) and the 450 nm laser used to excite 
the compound, luminescent images were collected in the A568 
channel. OMX SI reconstruction was performed on images. Imag-
es were processed and analyzed using FIJI Image J software Ð the 
SIM plugin was used to perform a 16-bit conversion.  
NHS ester-405 counterstain 
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Initial pellets were grown and fixed as before. After fixing the 
sample was washed with PBS. Cells were resuspended in PBS 
(250 µL), NHS-ester 405 was added (50 µg/mL). Samples were 
incubated on a rotary wheel at room temperature for 5 minutes. 
Cells were pelleted (14,000 RPM, 90 seconds) and washed with 
PBS (3 washes). Cell suspensions were mounted as previous. 
Laser 405 nm, emission filter DAPI. OMX SI reconstruction and 
OMX SI image registration was performed on the images, and the 
images were processed and analyzed using the FIJI Image J soft-
ware. 
HyVolution and STED microscopy  
Initial pellets were grown, fixed and mounted as previously dis-
cussed. Imaging was done on a commercial LEICA SP8 3X 
gSTED SMD confocal microscope (Leica Microsystems, Man-
heim, Germany), with capability of also performing high-
resolution microscopy via Hyvolution. The STED nanoscope is 
equipped with 3 depletion lines and it is also equipped with a 3D 
STED additional vortex to obtain higher spatially resolved images 
in XY and Z (enhanced axial super-resolution). The excitation 
laser beam consisted of a pulsed (80MHz) super-continuum white 
light laser (WLL). For a cleaner emission the excitation lines had 
a clean-up notch filter (NF) in the optical pathway. Images were 
taken using the pulsed White Light Laser (WLL) line excitation at 
475 nm, and recording the emission between 600-650 nm. The 
pulsed STED images were taken with a pulsed 775 nm depletion 
Laser, again in every case the respective NF were in place. The 
objective employed was a Leica 100x/1.4 NA oil objective. The 
pinhole was set at one Airy unit. The gated HyD detectors were 
set with the gated option on and the temporal gated selected was 
from 2 to 6.5ns. For the 3D STED images, the depletion lasers 
were split in two, the second vortex was set at 65%. For the Hyvo-
lution mode, the pinhole was set at 0.5 Airy units. Every image 
was acquired in the Leica HyD photon counting detectors.  
 
The Hyvolution technology, developed by Leica microsystems 
with the deconvolution Huygens software company (SVI, Nether-
lands), employs a reduced pinhole size at the detection pathway 
for the image acquisition. The image is later deconvoluted using 
the Huygens software package. The deconvolution software uses 
the raw data information from the Leica acquisition files for an 
optimal deconvolution, for 3D objects we employed a theoretical 
PSF, as it automatically counteracts the possible aberrations 
caused for in-depth imaging. The single plane images were de-
convolved with a theoretical calculated PSF provided by the soft-
ware and by an experimentally calculated PSF from fluorescent 
beads, in both cases no apparent difference was observed. Image 
analysis and deconvolution of STED images resolved the localisa-
tion and distribution of the organometallic dye at the bacteria. As 
expected the images had low intensity counts; to maximise signal-
to-noise we deconvolved the images using a commercially availa-
ble software (Huygens package software, SVI, Netherlands). To 
quantify the background level of noise we used either an automat-
ed quantification provided by the software or a manual by means 
of computing the averaged background intensity from regions 
outside the cell. We obtained better results with the manual pro-
cess. For the deconvolution we used 40 iterations, a signal to 
noise ratio of 15, and the classical maximum likelihood estimation 
method provided by the software. The quantification of the reso-
lution obtained at specific position on the bacteria was done em-
ploying the full width at half maximum (FWHM) method. The 
intensity line profiles over a distance drawn at the bacteria were 
represented using OriginPro ((OriginLab Corporation, Northamp-
ton, MA, U.S.A.)), and the calculation was done by fitting the 
peaks to a Gaussian function. The same software package was 
used for data plotting and analysis. The data was represented in 
form of normalized distribution population. The figures have been 
developed employing the free open source software Inkscape. The 
surface rendered images were obtained by Huygens Professional, 
LAX software (Leica SP8) to generate the surface rendered 3D 
STED images, and the orthogonal views, the rest of the images 
have been post processed with Fiji (ImageJ; NIH). 
 
Galleria Mellonella toxicity screen 
TruLarv
TM
 Galleria Mellonella were used for this study to ensure 
they were reared without antibiotics and were all a similar weight. 
For each compound concentration 7 Galleria were used, and for 
the control 15 Galleria were used. Insects were injected on the 
initial day with 10 µL of the correct concentration stock solution 
of 4
4+
 or water (control) into their left pro-leg. Once injected Gal-
leria were stored in a petri dish containing filter paper and incu-
bated at 37.5 ¼C. Three analysis tests were conducted at 0, 24, 48, 
72, 96 and 120 hours. Activity scores were recorded: 0-no move-
ment, 1-corrects itself, 2-movement on stimulation, 3-movement 
without stimulation. Live/dead scores recorded to produce per-
centage survival curves. Melanisation was scored on a scale of 0-
4: 0 Ð completely black, 1 Ð black spots, 2- tail/line black and 4 Ð 
none. Cocoon formation was not observed in this case. At the end 
of the toxicity screen Galleria were disposed of in a humane man-
ner. 
 
Transmission electron microscopy  
Cell pellets up until fixation were prepared in the same way as the 
single-stain super-resolution microscopy samples. The cells were 
fixed using 3% glutaraldehyde. Cells were dehydrated using a 
series of ethanol washes (70 Ð 100% ethanol) and TEM samples 
sectioned in Araldite resin by microtome. Samples were examined 
on a FEI Tecnai instrument operating at 80 kV equipped with a 
Gatan 1 K CCD camera. Images were processed and analyzed 
using FIJI Image J software. 
 
BacLight
TM
 membrane polarisation assay 
Membrane polarisation was studied using the Mol Probes Bac-
Light
TM 
polarisation kit. Overnight cultures of EC958 were grown 
as previously described. Cells were grown to the exponential 
phase (OD: 0.4) in GDMM at 37.5 ¡C. One solution of bacteria 
was treated with 4
4+ 
(1.6 µM) and incubated at for 60 minutes 
37.5 ¡C. The other solution was the untreated control. OD was 
measured and cells were diluted in PBS to a final concentrations 
of 10
6
 CFU/mL. Four flow cytometry tubes were prepared to 
sample. A,B: 1 mL of the cells treated with 4
4+ 
and the unstained 
control were incubated with 10 µL of DiOC2(3) (3 mM) for 30 
minutes in the dark in separate flow cytometry tubes. The mem-
brane polarisation positive control tube was prepared with 10 µL 
of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) (500 µM) 
10 µL of DiOC2(3) (3 mM), the cells were incubated for 30 
minutes in the dark before reading. In addition a fourth control 
was prepared in the absence of DiOC2(3) on 4
4+ 
stained cells. 
Readings were taken on an LSR II flow cytometer and data ana-
lysed using the FlowJo softwate. 
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